References
-
1.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020:105954. [PubMed ID: 32234467]. [PubMed Central ID: PMC7118634]. https://doi.org/10.1016/j.ijantimicag.2020.105954.
-
2.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. [PubMed ID: 32192578]. https://doi.org/10.1016/S0140-6736(20)30628-0.
-
3.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020. [PubMed ID: 32350134]. https://doi.org/10.1073/pnas.2005615117.
-
4.
Hashemi-Meshkini A, Nikfar S, Glaser E, Jamshidi A, Hosseini SA. Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. Value Health Reg Issues. 2016;9:42-8. [PubMed ID: 27881258]. https://doi.org/10.1016/j.vhri.2015.10.003.
-
5.
Mendis S, Fukino K, Cameron A, Laing R, Filipe AJ, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85(4):279-88. [PubMed ID: 17546309]. [PubMed Central ID: PMC2636320]. https://doi.org/10.2471/blt.06.033647.